A national drug policy reform organization is challenging the DEA’s proposal to ban two psychedelic substances, arguing the move would hinder critical scientific research. As reported by Marijuana Moment, the nonprofit Students for Sensible Drug Policy (SSDP) presented their case in a prehearing statement to the DEA’s administrative court on Tuesday. The DEA plans to classify 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I drugs under the Controlled Substances Act (CSA). This classification is reserved for substances with high abuse potential and…